Milan Radovich
Chief Scientific Officer & Head, Business Development Caris Life Sciences
Seminars
Tuesday 6th October 2026
Panel Discussion: The Role of AI in the Future of Companion Diagnostics
5:10 pm
- Companion diagnostics have traditionally relied on single-gene or single-analyte biomarkers to identify the right patients for a therapy. The field is now evolving toward RNA expression, complex signatures, digital pathology, multi-omic data, and AI-enabled approaches to patient selection
- This panel will explore the future of companion diagnostics as biomarkers become increasingly complex, multimodal, and AI-derived. Importantly, how AI-enabled CDx can be developed, validated, and regulated without compromising the rigor required for treatment decisions
Wednesday 7th October 2026
Panel Discussion: Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment
11:20 am
- One Frontier Model, For Every Stage of Drug Development: Discover how a unified ecosystem powered by a single frontier AI model streamlines biomarker discovery, clinical trial stratification, regulatory-grade diagnostics, and global deployment to pathology labs. Platform agnostic development under one roof – no need for algorithm hand-offs or tedious integrations before deployment
- De-Risking CDx Timelines With Tissue AI: AI-driven biomarker signal detection reduces trial enrollment risk and enables more informed decisions from less tissue — shortening Rx-Dx co-development time
- Redefining Global Pathology Routine: Moving tissue biomarkers from isolated reference labs to global clinical routine powered by our extensive CRO partnerships and an active lab network
